MAXCYTE, INC. — Investor Relations & Filings
MaxCyte, Inc. is a cell-engineering company that provides enabling platform technologies to advance the discovery, development, and commercialization of cell-based therapeutics. Its core offering is the ExPERT™ platform, which utilizes proprietary Flow Electroporation® technology for efficient, scalable, and non-viral transfection of complex cells. This technology supports a wide range of applications, including cell therapy, gene editing, antibody and protein production, and vaccine development. Additionally, MaxCyte offers SeQure™ genotoxicity assessment services to evaluate the safety of gene-edited products by detecting on- and off-target effects. The company employs a partnership-driven licensing model to support clients from early-stage research through to clinical and commercial manufacturing.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 8-K - MAXCYTE, INC. (0001287098) (Filer) | 2026-03-27 | English | |
| SCHEDULE 13G/A - MAXCYTE, INC. (0001287098) (Subject) | 2026-03-27 | English | |
| SCHEDULE 13G Filing | 2026-02-05 | English | |
| 8-K Filing | 2026-01-12 | English | |
| Major Shareholding Notification 2025 | 2025-11-14 | English | |
| 10-Q | 2025-11-13 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
4 filings
| |||||
| 33065964 | 8-K - MAXCYTE, INC. (0001287098) (Filer) | 2026-03-27 | English | ||
| 33061623 | SCHEDULE 13G/A - MAXCYTE, INC. (0001287098) (Subject) | 2026-03-27 | English | ||
| 28677652 | SCHEDULE 13G Filing | 2026-02-05 | English | ||
| 28677654 | 8-K Filing | 2026-01-12 | English | ||
|
2025
11 filings
| |||||
| 11680606 | Major Shareholding Notification 2025 | 2025-11-14 | English | ||
| 11680607 | 10-Q | 2025-11-13 | English | ||
| 11680611 | 8-K | 2025-11-12 | English | ||
| 11680609 | 8-K | 2025-11-05 | English | ||
| 11680608 | Major Shareholding Notification 2025 | 2025-11-04 | English | ||
| 11680610 | Major Shareholding Notification 2025 | 2025-11-03 | English | ||
| 11680612 | Major Shareholding Notification 2025 | 2025-10-24 | English | ||
| 11680613 | 8-K | 2025-09-22 | English | ||
| 11680614 | Director's Dealing 2025 | 2025-08-27 | English | ||
| 11680615 | FORM S-8 | 2025-08-26 | English | ||
| 11680616 | Director's Dealing 2025 | 2025-08-13 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Hipower Energy Spolka Akcyjna
Develops and commercializes hydrogen-based solutions and fu…
|
HPE | PL | Professional, scientific and te… |
|
HitGen Inc.
Discovers small molecule drug candidates using a DNA-encode…
|
688222 | CN | Professional, scientific and te… |
|
HLB bioStep Co.,Ltd.
A non-clinical CRO providing drug development services, spe…
|
278650 | KR | Professional, scientific and te… |
|
HLB PANAGENE Co., LTD.
Specializes in PNA-based molecular diagnostics for oncology…
|
046210 | KR | Professional, scientific and te… |
|
HLB SCIENCE Inc.
Develops drugs and diagnostics for infectious, immune, and …
|
343090 | KR | Professional, scientific and te… |
|
Hoth Therapeutics, Inc.
A clinical-stage biopharma company advancing drugs for unme…
|
HOTH | US | Professional, scientific and te… |
|
Human Stem Cells Institute PJSC
Develops gene therapies, vaccines, medical devices, and gen…
|
ISKJ | RU | Professional, scientific and te… |
|
HVIVO PLC
A contract research organization specializing in human chal…
|
HVO | GB | Professional, scientific and te… |
|
Hybrigenics SA
Provider of technologies for studying molecular interaction…
|
ALHYG | FR | Professional, scientific and te… |
|
Hyundai ADM Bio lnc.
A contract research organization providing clinical trial s…
|
187660 | KR | Professional, scientific and te… |
MAXCYTE, INC. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/10520/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=10520 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=10520 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=10520 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 10520}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for MAXCYTE, INC. (id: 10520)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.